Characteristics | Studies (n) | Pooled sensitivity (95% Cl) | Pooled specificity (95% Cl) |
---|---|---|---|
Total | 10 | 0.82 (0.70–0.90) | 0.81 (0.72–0.87) |
Year | |||
  > 2011 | 6 | 0.86 (0.75–0.97) | 0.81 (0.71–0.90) |
  ≤ 2011 | 4 | 0.76 (0.59–0.93) | 0.80 (0.69–0.92) |
Design | |||
 Retrospective | 5 | 0.74 (0.58–0.90) | 0.75 (0.65–0.84) |
 Prospective | 5 | 0.90 (0.81–0.99) | 0.87 (0.79–0.95) |
No. of nodules | |||
  ≤ 100 | 6 | 0.81 (0.69–0.94) | 0.84 (0.77–0.92) |
  > 100 | 4 | 0.83 (0.69–0.98) | 0.74 (0.61–0.86) |
Lesion diameter* | |||
 Only nodules(≤ 3 cm) | 4 | 0.67 (0.58–0.76) | 0.86 (0.80–0.92) |
 Nodules and masses | 2 | 0.97 (0.93–1.00) | 0.82 (0.69–0.95) |
Disease in the benign group | |||
 Inflammation only | 2 | 0.81 (0.60–1.00) | 0.88 (0.76–1.00) |
 Inflammation and tumors | 8 | 0.82 (0.71–0.93) | 0.79 (0.70–0.87) |
 Parameter | |||
 SUVmax | 6 | 0.86 (0.75–0.97) | 0.78 (0.68–0.88) |
 SUV-CR | 4 | 0.77 (0.60–0.93) | 0.84 (0.74–0.94) |
Reference standard | |||
 His/Fol | 7 | 0.75 (0.65–0.85) | 0.82 (0.73–0.90) |
 His | 3 | 0.92 (0.84–0.99) | 0.79 (0.65–0.93) |